Acurx Pharmaceuticals presented a study showing ibezapolstat (IBZ) outperforms vancomycin and fidaxomicin in killing Clostridioides difficile and vancomycin-resistant Enterococcus (VRE) in lab tests. IBZ maintained strong bactericidal activity even in complex co-cultures where Enterococcus impairs other antibiotics' effectiveness. It also reduced toxin B expression and VRE overgrowth, suggesting potential to improve treatment and reduce recurrence of C. difficile infection (CDI). The company is advancing IBZ into Phase 3 trials, aiming for FDA approval to treat and prevent recurrent CDI, a major healthcare challenge with high costs and mortality.
NVIDIA and Palantir both reported strong quarterly results, highlighting unstoppable AI growth. NVIDIA focuses on the physical infrastructure powering AI models, with revenue up 106% and a strong data center segment. Palantir excels in software that ...
The upcoming US Senate vote on the CLARITY Act, which aims to clarify regulatory authority over cryptocurrencies, threatens a $9.46 million short squeeze in XRP if the price rises just 5% to $1.4644. Currently trading around $1.40, XRP is near a tech...
Intel reported its strongest revenue growth in over 15 years with Q2 2026 revenue hitting $16.128 billion, driven by a 59% surge in Data Center and AI revenue. Shares have tripled in the past year, rising 318%, but momentum is slowing due to ongoing ...
Waters Corporation has launched the BD FACSDiscover A7 Cell Analyzer, a new flow cytometry device that offers high spectral resolution and sensitivity with advanced standardization features. It enables researchers to analyze over 50 cell parameters c...
Railtown AI Technologies Inc. will participate in ALL IN 2026, Canada's premier AI and tech event held in Montreal on September 16-17, 2026. The company will join the British Columbia delegation and co-sponsor their exhibition booth, showcasing its C...
